Nonclinical studies demonstrated that FMC-376 results in tumor regression in multiple mouse models including PDX models of NSCLC, PDAC and CR [72–74], suggesting its ability to overcome resistance to KRAS G12C (OFF) inhibitors. Here, KRAS is linked to neoplasm.